SeminarCirculating free tumor DNA and colorectal cancerADN libre circulant d’origine tumorale et cancer colorectal
Introduction
A number of alterations occurring in cells and biological molecules during the course of neoplastic processes can be considered markers of cancer, and advances in genomics and proteomics now make it possible to identify such markers in plasma and serum, as well as in other bodily fluids such as urine, pancreatic juice, fecal matter and saliva. This makes these biological media highly useful for screening and making the diagnosis, and for determining the patient's prognosis and therapeutic assessment. In patients with solid tumors, management decisions are made on the basis of clinical, histological and, more rarely, molecular factors, yet the overall picture—given the heterogeneous nature of tumorigenesis—remains imperfect, making it difficult to determine the most appropriate diagnostic or therapeutic strategy. However, one of the characteristic features of cancer cells is the presence of genetic anomalies (amplifications, deletions, point mutations, chromosomal translocations, microsatellite instability [MSI]) and/or epigenetic alterations (promoter gene hypermethylation, acetylation) that perturb the expression of the genes controlling critical cell processes, such as proliferation, differentiation, the cell cycle, apoptosis and angiogenesis [1].
Thus, an improved knowledge of the molecular biology of cancer can be expected to open the way for new perspectives not only in fundamental research (better understanding of carcinogenesis), but also in drug development (for example, the currently rapidly developing ‘target-therapy’ approach) and clinical management (use of biomarkers to establish the diagnosis or prognosis, or to predict response to treatment). Previous research has demonstrated that either plasma or serum can contain a small quantity of free (non-cell-bound) circulating DNA. Concentrations of this free circulating DNA, in the order of a few nanograms per milliliter (ng/mL), increase significantly in patients with cancer compared with healthy subjects [2]. Also, there is clear evidence that, in cancer patients, a fraction of this DNA is tumor-derived, as the genetic and/or epigenetic molecular alterations characteristic of the tumor are found in the free DNA circulating in the plasma or serum. In fact, molecular alterations characteristic of the majority of solid tumors have been detected in the serum or plasma of cancer patients [3]. However, most of the research into the detection of free tumor-derived DNA in blood samples, and in other biological samples such as fecal matter, urine or pancreatic juice, is still in the preliminary stage. Nevertheless, this molecular approach to the detection of free circulating tumor-associated DNA in non-tumor biological samples introduces exciting new perspectives for the diagnosis and follow-up of patients with cancer.
Section snippets
Free cirulating DNA in plasma and serum
Free circulating DNA was first reported in serum from patients with systemic lupus erythematosus, rheumathoid arthitis and glomerulonephritis [4], [5], [6], [7], [8]. Leon et al. [2] were the first to report that cancer patients presented with higher levels of such non-cell-bound circulating DNA in their blood than did patients with non-cancerous diseases. These findings were later confirmed in a series of patients with gastrointestinal cancer [9]. The mean concentration of free DNA circulating
Molecular alterations of plasma or serum free circulating DNA in colorectal cancer
When precisely characterized, genetic or epigenetic molecular alterations of cancer-cell DNA should offer a means of identifying the presence of cancer-cell DNA in biological samples. PCR has enabled the development of sensitive, specific and reproducible molecular-biology techniques that can demonstrate the presence of one altered gene copy in 10,000 to 100,000 normal copies. Such diagnostic techniques have been used for years to detect residual disease in bone-marrow samples from patients
Free tumor-derived circulating DNA in plasma or serum: a biomarker with prognostic value and/or predictive of treatment effect in colorectal cancer
In light of the growing complexity of management strategies for colorectal cancer, it is essential to validate any new prognostic factors that could be used to identify subgroups of patients who may be expected to benefit from the various therapeutic strategies. For a given type of cancer at a given stage, the expected beneficial effect of a particular therapeutic strategy is never observed in all patients. The reason is undoubtedly related to the biological heterogeneity of most solid tumors.
Conclusion
The identification of new markers of colorectal cancer responds to the need for new sensitive and specific biological tests to enable earlier diagnosis, more accurate evaluation of the prognosis and earlier detection of recurrent disease, while also offering new directions towards the development of other diagnostic and/or therapeutic strategies to improve the prognosis. Cell-free circulating tumor-associated DNA, easily detectable in blood and possibly urine, is a potentially attractive
Conflict of interest statement
None.
References (136)
- et al.
The hallmarks of cancer
Cell
(2000) - et al.
Circulating nucleic acids (CNAs) and cancer–a survey
Biochim Biophys Acta
(2007) - et al.
Cell-free DNA: measurement in various carcinomas and establishment of normal reference range
Clin Chim Acta
(2002) - et al.
Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer
Cancer Lett
(2008) - et al.
Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours
Cancer Lett
(1995) - et al.
Isolation and characterization of DNA from the plasma of cancer patients
Eur J Cancer Clin Oncol
(1987) - et al.
About the possible origin and mechanism of circulating DNA apoptosis and active DNA release
Clin Chim Acta
(2001) - et al.
Rapid clearance of fetal DNA from maternal plasma
Am J Hum Genet
(1999) - et al.
Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization
Blood
(1994) - et al.
K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer
Gastroenterology
(1997)